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Background
Patients with Turner’s syndrome have increased cardio-
vascular (CV) morbidity and mortality, potentially over
and above that explained by the higher rate of both con-
genital heart disease and associated endocrine disorders
and hypertension. GH administration to maximise adult
height is a well-established treatment form but may
affect cardiovascular status, ventricular mechanics and
myocardial function. Furthermore, given the adverse CV
effects of supra-physiological GH levels associated with
acromegaly and in the field of sports doping, concern
has been voiced about potential risks associated with
this form of treatment.
CMR based strain derivatives offer advanced analysis
of myocardial deformation and function. Such technolo-
gies are thought to increase sensitivity and may allow
detection of “pre-clinical” disease not apparent by
assessment of conventional parameters such as ventricu-
lar volumes and ejection fraction (EF).
Methods
52 patients with Turner syndrome underwent a compre-
hensive CV CMR study. Patients with structural heart
disease such as aortic coarctation, haemodynamically
important valve disease, previous myocardial infarction
or cardiac surgery were excluded. Of the remaining 35
adult patients 14 had a history of previous exposure to
GH (GH +ve), 21 had no history of GH treatment (GH
-ve).
Assessment of ventricular mass, volumes and derived
EF was performed by means of signal intensity thresh-
olding based detailed endocardial contouring using
commercial software (CMRtoolsTM, Cardiovascular
Imaging Solutions Ltd, UK). LV/RV longitudinal and LV
circumferential strain was analysed using an endocardial
feature tracking software package (2D-CPA MR, Dio-
genes®, TomTec Imaging Systems GmbH, Germany).
Results
The demographic and haemodynamic data of both
groups is summarised in Table 1. The mean age of GH
initiation was 10 ± 4.1 years, with a mean duration of
treatment of 3.7 years. Ventricular volumes and perfor-
mance parameters are summarised in Table 2. Conven-
tional resting volumetric measurements and
performance indices, as well as biventricular strain mea-
surements, were within normal limits and did not differ
significantly between groups.
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Table 1 Demographic and haemodynamic parameter
data in Turner’s syndrome women with a positive and
negative history of growth hormone exposure. Values







Age (yrs) 31.4 ± 9.8 37.4 ± 7.6 0.05
Weight (kg) 64.9 ± 16.8 69.0 ± 16.2 0.48
Height (m) 1.48 ± 0.07 1.48 ± 0.08 0.83
BMI 29.0 ± 6.5 31.5 ± 6.4 0.28
BSA (m2) 1.6 ± 0.2 1.6 ± 0.05 0.62
Heart Rate (bpm) 83 ± 15 84 ± 14 0.89
Blood pressure (mmHg) systolic
diastolic
116 ± 20 118 ± 17 0.67
73 ± 12 77 ± 12 0.31
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Conclusions
Childhood GH exposure appears to have no detectable
detrimental late effects on LV/RV ventricular perfor-
mance. This study therefore provides further reassur-
ance regarding the long term safety of childhood GH
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Table 2 Volumetric and strain analysis data
GH +ve (n=14) GH -ve (n=21) P value
Indexed LV EDV (ml/m2) 68.9 ± 9.3 63.6 ± 11.7 0.22
Indexed LV ESV (ml/m2) 23.1 ± 6.1 18.8 ± 6.7 0.10
LVEF (%) 67 ± 6.0 71 ± 6.8 0.16
LV mass (g/m2) 44 ± 7.3 42 ± 7.6 0.98
TAPSE (cm) 2.2 ± 0.5 2.1 ± 0.3 0.33
Longitudinal LV strain (%) -17.7 ± 1.9 -18.2 ± 4.2 0.69
Longitudinal RV strain (%) -28.7 ± 5.5 -25.3 ± 6.6 0.12
Circumferential LV strain (%) -27.8 ± 4.5 -27.7 ± 5.5 0.96
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